Abstract:Background: Patients with mucopolysaccharidosis (MPS) often face delayed diagnoses, limited treatment options and high healthcare costs, that may significantly affect patients' quality of life. The objective of this study was to understand medical service utilization related to diagnosis and treatment, economic burden during diagnosis period, and health-related quality of life among MPS patients in China. Methods: A series of patients diagnosed with MPS registered in the national patient organization were recruited for a cross-sectional survey from May to July 2019. Information were collected from patients or their parents via phone interview, including demographic data, utilization of services related to diagnosis and treatment, total cost during the period of MPS diagnosis and health-related quality of life (HRQoL). HRQoL was assessed by PedsQL 4.0 Generic Core Scale (PedsQL) and 36-item short-form health survey (SF-36) depending on the age of patients with MPS and compared with the general Chinese population. Results: A total of 180 MPS patients (50, 67, 15, 46, 1 and 1 for type I, II, III, IV, VI and VII), with a mean age of 9.54 years and 137 (76.11%) males, were included in analysis. The mean age at first visit to a medical doctor for MPS related symptoms was 3.65 ± 2.58 years old, while only 12 patients (6.67%) were diagnosed on their first visit. The mean diagnostic delay, which is defined as the time between the first visit to a medical doctor for MPS related symptoms and the final diagnosis, was 9.42 months, with no significant difference between types. The average number of misdiagnosis was 4.56. Before the confirmed diagnosis, the patients made an average of 6.31 visits and visited 4.3 hospitals. During diagnosis period, the mean of ¥81,086.72 direct medical costs accounted for 63.75% of the total cost. Only 32.78% of the patients had ever received specific treatments. The mean scores of PedsQL and SF-36 of patients were significantly lower than the Chinese norms. Household annual income per person, specific treatment use and MPS subtype were significantly associated HRQoL of patients. Conclusion: The results highlight challenges faced by MPS patients in terms of diagnosis, access to specific treatments, economic burden and low HRQoL. There is an urgent need to improve early detection and diagnosis, create fair and consistent mechanisms to increase access to specialized treatment and reduce the economic burden of MPS patients in China.

Study on the disease burden of patients with mucopolysaccharidosis type II in China

Clinical characteristics and genotypes of 201 patients with mucopolysaccharidosis type II in China: A retrospective, observational study.

Phenotypic and genetic characteristics of 130 patients with mucopolysaccharidosis type II: A single-center retrospective study in China

Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China

The diagnosis and management of mucopolysaccharidosis type II

Current status and progress of mucopolysaccharidosis type Ⅰ

Mucopolysaccharidosis type IIIC in chinese mainland: clinical and molecular characteristics of ten patients and report of six novel variants in the HGSNAT gene

Detailed Pedigree Analyses and Prenatal Diagnosis for a Family with Mucopolysaccharidosis Type II.

Identification and characterization of novel genetic variants in the first Chinese family of mucopolysaccharidosis IIIC (Sanfilippo C syndrome)

[Enzymatic Diagnosis of 47 Cases with Mucopolysaccharidosis].

A Novel Iduronate 2-Sulfatase Mutation in a Chinese Family with Mucopolysaccharidosis Type II

Incidence of the Mucopolysaccharidoses in Taiwan, 1984–2004

Updated Confirmatory Diagnosis for Mucopolysaccharidoses in Taiwanese Infants and the Application of Gene Variants

Clinical manifestations and genetic mutation analysis of patients with mucopolysaccharidosis type VII in China

Mucopolysaccharidosis Type Ⅱ: a Progress on Molecular Genetics

Mucopolysaccharidosis III in Mainland China: natural history, clinical and molecular characteristics of 34 patients

Natural History and Clinical Assessment of Taiwanese Patients with Mucopolysaccharidosis IVA

Clinical Characteristics and Surgical History of Taiwanese Patients with Mucopolysaccharidosis Type II: Data from the Hunter Outcome Survey (HOS).

Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan

[Molecular Analysis of IDS Gene and Prenatal Diagnosis in a Chinese Family with Mucopolysaccharidosis Type II].

Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells